Lamarca A, et al.
European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours.
J Neuroendocrinol 2024, 36: e13423 (free full text).

Goudet P, et al.
French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1.
Ann Endocrinol 2024, 85: 2-19 (free full text).

Kos-Kudła B, et al.
European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours.
J Neuroendocrinol 2023, 35: ce13343 (free full text).

Hofland J, et al.
European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.
J Neuroendocrinol 2023, 35: e13318 (free full text).

Panzuto F, et al.
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1–G3.
J Neuroendocrinol 2023, 35: e13306 (free full text).

Eads JR, et al.
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
Endocr Relat Cancer 2023, 30: e220206 (free full text).

Rinke A, et al.
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for colorectal neuroendocrine tumours.
J Neuroendocrinol 2023, 35: e13309 (free full text).

Sorbye H, et al.
European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma.
J Neuroendocrinol 2023, 35: e13249 (free full text).

Grozinsky-Glasberg S, et al.
European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease.
J Neuroendocrinol 2022, 34: e13146 (free full text).

Dromaine C, et al.
ENETS consensus guidelines for synoptic reporting of radiology studies.
J Neuroendocrinol DOI: 10.1111/jne.13060 (free full text).

Gallo M, Adinolfi V, Morviducci L, et al.
Early prediction of pancreatic cancer from new-onset diabetes: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
ESMO Open 2021, 6: 100155 (free full text).

Silvestris N, Argentiero A, Natalicchio A, et al.
Antineoplastic dosing in overweight and obese cancer patients: an Associazione Italiana Oncologia Medica (AIOM)/Associazione Medici Diabetologi (AMD)/Società Italiana Endocrinologia (SIE)/Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
ESMO Open 2021, 6: 100153 (free full text).

Silvestris N, Argentiero A, Beretta G, et al.
Management of metabolic side effects from targeted therapies and immune checkpoint inhibitors in cancer patients: an Associazione Italiana di Oncologia Medica (AIOM), Associazione Medici Diabetologi (AMD), Società Italiana Farmacologia (SIF) multidisciplinary consensus position paper.
Crit Rev Oncol Hematol 2020, 154: 103066.

Castinetti F, Albarel F, Archambeaud F, et al.
French Endocrine Society Guidance on endocrine side effects of immunotherapy.
Endocr Relat Cancer 2019, 26: G1-18 (free full text).

Brahmer JR, Lacchetti C, Schneider BJ, et al; National Comprehensive Cancer Network.
Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline.
J Clin Oncol 2018, 36: 1714-68 (free full text).

Higham CE, Olsson-Brown A, Carroll P, et al; Society for Endocrinology Clinical Committee.
Society For Endocrinology endocrine emergency guidance: acute management of the endocrine complications of checkpoint inhibitor therapy.
Endocr Connect 2018, 7: G1-7.

Sklar CA, Antal Z, Chemaitilly W, Cohen LE, Follin C, Meacham LR, Murad MH.
Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline.
J Clin Endocrinol Metab 2018, 103: 2761–84 (free full text).

Haanen JBAG, Carbonnel F, Robert C, et al; ESMO Guidelines Committee.
Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
Ann Oncol 2017, 28 (suppl 4): iv119-42 (free full text).

Puzanov I, Diab A, Abdallah K, et al; Society for Immunotherapy of Cancer Toxicity Management Working Group.
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
J Immunother Cancer 2017, 5: 95 (free full text).

Perren A, Couvelard A, Scoazec JY, et al.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology: Diagnosis and Prognostic Stratification.
Neuroendocrinology 2017, 105: 196-200.

Oberg K, Couvelard A, Delle Fave G, et al.
ENETS Consensus Guidelines for standard of care in Neuroendocrine Tumours: Biochemical Markers.
Neuroendocrinology 2017, 105: 201-11.

Sundin A, Arnold R, Baudin E, et al.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine & Hybrid Imaging.
Neuroendocrinology 2017, 105: 212-44.

Partelli S, Bartsch DK, Capdevila J, et al.
ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.
Neuroendocrinology 2017, 105: 255-65.

Pavel M, Valle J, Eriksson B, et al.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy ‐ Biotherapy and Novel Targeted Agents.
Neuroendocrinology 2017, 105: 266-80.

Garcia-Carbonero R, Rinke A, Valle JW, et al.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms. Systemic Therapy 2: Chemotherapy.
Neuroendocrinology 2017, 105: 281-94.

Hicks RJ, et al.
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.
Neuroendocrinology 2017, 105: 295-309.

Falconi M, Eriksson B, Kaltsas G, et al, and all other Vienna Consensus Conference participants.
ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.
Neuroendocrinology 2016, 103 (2): 153-171.

Niederle B, Pape UF, Costa F, et al, and all other Vienna Consensus Conference participants.
ENETS Consensus Guidelines update for neuroendocrine neoplasm of the jejunum and ileum.
Neuroendocrinology 2016, 103:125-138.

Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al, and all other Vienna Consensus Conference participants.
ENETS consensus guidelines update for gastroduodenal neuroendocrine neoplasms.
Neuroendocrinology 2016, 103 (2): 119-124.

Pavel M, O'Toole D, Costa F, Capdevila J, et al, and all other Vienna Consensus Conference participants.
ENETS Consensus Guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site.
Neuroendocrinology 2016, 103:172-185.

Associazione Italiana Oncologia Medica.
Linee guida Neoplasie Neuroendocrine (in condivisione con It.a.net.)
2016 (free full text).

AIOM - SIE – SIGO.
Raccomandazioni su oncofertilità (free full text).

AIOM.
Linee guida neoplasie dell’utero: endometrio e cervice.
2015 (free full text).

Pavel M, Grossman A, Arnold R, et al.
ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors.
Neuroendocrinology 2010, 91: 326–32. 

Kianmanesh R, Ruszniewski P, Rindi G, et al.
ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors.
Neuroendocrinology 2010, 91: 333–40. 

Kos-Kudła B, O’Toole D, Falconi M, et al.
ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors.
Neuroendocrinology 2010, 91: 341–50.